

**IN THE UNITED STATES DISTRICT COURT  
FOR THE NORTHERN DISTRICT OF OKLAHOMA**

(1) THE BOARD OF COUNTY )  
COMMISSIONERS OF THE COUNTY )  
OF TULSA, )  
Plaintiff, ) Case No. CIV-19-205-GKF-FHM  
v. ) (Removal from: District Court  
Defendants. ) of Tulsa County, Case No. CJ-2019-1116)

(1) PURDUE PHARMA L.P., et al., )

**SPECIAL APPERANCE AND CORPORATE DISCLOSURE STATEMENT  
OF DEFENDANTS TEVA PHARMACEUTICALS USA, INC.,  
CEPHALON, INC., ACTAVIS LLC, ACTAVIS PHARMA, INC.  
AND WATSON LABORATORIES, INC.**

Pursuant to Federal Rule of Civil Procedure 7.1, Defendants Teva Pharmaceuticals USA, Inc. (“Teva USA”), Cephalon, Inc. (“Cephalon”), Watson Laboratories, Inc. (“Watson”), Actavis LLC (“Actavis LLC”), and Actavis Pharma, Inc. f/k/a Watson Pharma, Inc. (“Actavis Pharma”), appear specially and expressly reserve all available defenses, including but not limited to those related to service of process and personal jurisdiction. Without waving any available defense Defendants make the following disclosures:

1. Defendant Cephalon is directly owned by Cupric Holding Co., Inc., which is directly owned by Teva Pharmaceutical Industries Ltd. (“Teva Ltd.”).
2. Teva Ltd. does not have a parent corporation and no publicly held corporation holds more than 10% or more of its stock.
3. Defendant Teva USA is directly owned by: (i) Orvet UK Unlimited (Majority

Shareholder), which is directly owned by Teva Pharmaceuticals Europe B.V., which is directly owned by Teva Ltd.; and (ii) Teva Pharmaceutical Holdings Coöperatieve U.A. (Minority Shareholder), which is directly owned by IVAX LLC, a direct subsidiary of Teva USA.

4. Defendants Watson, Actavis LLC, and Actavis Pharma are wholly-owned indirect subsidiaries of Teva Ltd.

Respectively Submitted,

/s/ Ashley E. Quinn

ROBERT G. McCAMPBELL, OBA No. 10390  
NICHOLAS V. MERKLEY, OBA No. 20284  
KYLE D. EVANS, OBA No. 22135  
ASHLEY E. QUINN, OBA No. 33251

**GABLEGOTWALS**

One Leadership Square, 15th Fl.  
211 North Robinson  
Oklahoma City, OK 73102-7255  
Telephone: (405) 235-3314

[RMcCampbell@Gablelaw.com](mailto:RMcCampbell@Gablelaw.com)

[NMerkley@Gablelaw.com](mailto:NMerkley@Gablelaw.com)

[KEvans@Gablelaw.com](mailto:KEvans@Gablelaw.com)

[AQuinn@Gablelaw.com](mailto:AQuinn@Gablelaw.com)

and

Harvey Bartle, IV\*  
MORGAN, LEWIS & BOCKIUS LLP  
502 Carnegie Center  
Princeton, New Jersey 08540-6241  
T: (609) 919-6685  
F: (609) 919-6701  
[harvey.bartle@morganlewis.com](mailto:harvey.bartle@morganlewis.com)

and

Steven A. Reed\*  
MORGAN, LEWIS & BOCKIUS LLP  
1701 Market Street  
Philadelphia, PA 19103  
T: 215.963.5000  
F: 215.963.5001

[steven.reed@morganlewis.com](mailto:steven.reed@morganlewis.com)

and

Brian M. Ercole\*

MORGAN, LEWIS & BOCKIUS LLP

200 S. Biscayne Blvd., Suite 5300

Miami, FL 33131-2339

T: 305.415.3000

F: 305.415.3001

[brian.ercole@morganlewis.com](mailto:brian.ercole@morganlewis.com)

\* denotes national counsel who will seek

pro hac vice admission

**Attorneys for Defendants Teva**

**Pharmaceuticals, USA, Inc., Cephalon, Inc.,**

**Watson Laboratories, Inc., Actavis LLC, and**

**Actavis Pharma, Inc. F/K/A Watson Pharma,**

**Inc.**

### **CERTIFICATE OF SERVICE**

I hereby certify that on this 30th day of April, 2019, I electronically transmitted the foregoing document to the Court Clerk using the ECF System for filing. Based on the records currently on file, the Court Clerk will transmit a Notice of Electronic Filing to all ECF registrants.

*/s/ Ashley E. Quinn*

---

Ashley E. Quinn